Shopping Cart 0
Cart Subtotal
AED 0

KOL Perspectives: Implementation of the treat-to-target approach in IBD

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 9175

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 18350

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 27525

Details

KOL Perspectives: Implementation of the treat-to-target approach in IBD

Summary

This KOL Insight briefing focuses on KOLs views of implementation of the treat-to-target approach in IBD.

The briefing includes analysis of KOL opinion on the following topic areas-

- Perceptions of the CALM study and potential impact on Crohn's disease clinical management

- Adoption of a T2T approach in UC

- Impact of T2T studies on choice of therapy

- Monitoring mucosal healing in IBD

Key Highlights

- Most KOLs view the data from the CALM study as supportive of the concept of a T2T strategy in Crohn's disease

- T2T is used routinely in clinical practice, with an increase in a patient's disease severity used as a driver for adoption of the strategy

- Over half the KOLs expect the CALM study to positively influence Crohn's disease management across clinical practice.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our inflammatory bowel disease key opinion leaders (KOLs)

- In total, we conducted interviews with 10 KOLs: 5 Europe-based & 5 N. America-based

- Interviews performed during December 2017

- KOL data is analyzed to produce: Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts.

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "implementation of a treat-to-target (T2T) approach in IBD"

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Table Of Content

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Adalimumab, CALM treat-to-target, T2T, IBD


Companies

AbbVie

Prometheus

Janssen

Company Profile

Company Profile Title

KOL Perspectives: Implementation of the treat-to-target approach in IBD

Summary

This KOL Insight briefing focuses on KOLs views of implementation of the treat-to-target approach in IBD.

The briefing includes analysis of KOL opinion on the following topic areas-

- Perceptions of the CALM study and potential impact on Crohn's disease clinical management

- Adoption of a T2T approach in UC

- Impact of T2T studies on choice of therapy

- Monitoring mucosal healing in IBD

Key Highlights

- Most KOLs view the data from the CALM study as supportive of the concept of a T2T strategy in Crohn's disease

- T2T is used routinely in clinical practice, with an increase in a patient's disease severity used as a driver for adoption of the strategy

- Over half the KOLs expect the CALM study to positively influence Crohn's disease management across clinical practice.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our inflammatory bowel disease key opinion leaders (KOLs)

- In total, we conducted interviews with 10 KOLs: 5 Europe-based & 5 N. America-based

- Interviews performed during December 2017

- KOL data is analyzed to produce: Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts.

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "implementation of a treat-to-target (T2T) approach in IBD"

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Adalimumab, CALM treat-to-target, T2T, IBD


Companies

AbbVie

Prometheus

Janssen